In 2013, open-access journal PLOS ONE again posted a record year for new publications, with 31,500 scientific articles added to the site. The haul took the journal past the 100,000 article mark but also created new challenges.
New York-based biopharma Regeneron will sequence DNA from 100,000 patients at Geisinger Health Systems, a healthcare network that serves 3 million people in Pennsylvania.
The merger expands the range of medical imaging services BioClinica can offer while also moving it into new areas, notably clinical trial services and patient recruitment.
As part of Horizon 2020, the European Union's $100 billion initiative to secure the competitiveness of the region through investment in innovative projects, the EU is setting aside an initial $40 million for companies that can turn data into discoveries.
At the J.P. Morgan Healthcare Conference this week, Illumina unveiled a system to kick-start the era of low-cost, industrial-scale sequencing of human genomes.
With the deadline for publication of long-awaited FDA guidance on online drug promotion now just 6 months away, the FDA has got the ball rolling early, posting an unexpected document outlining its views on how and when companies should submit online promotional materials for review.
Standing out in the congested genomics data analysis market is a challenge for startups, with each month bringing news of rivals' fresh investments and products. Maverix Biomics is one of many companies trying to gain a foothold in the sector, but it can boast a differentiating factor--one of Google's original angel investors has contributed funding.
With the spiraling amount of time and money needed to bring a drug to market weighing heavy on their Big Pharma clients, CROs have invested in efficiency boosting technology to gain a competitive edge. And the trend is tipped to continue, with an analyst predicting CROs will be at the forefront of developments in IT and genomics in 2014.
Since setting up shop in 2006, WellDoc has financed development of its mobile diabetes management tool through debt and angel investment, snagging itself the input of pharma veterans in the process. Now, it has landed its first round of institutional investment, with Merck Global Health Innovation Fund and others committing $20 million.
The past year was tough for Merge Healthcare. An anticipated private equity takeover never happened and in August disastrous results prompted a 46% fall in its stock. Now Merge faces fresh misery after an investigation revealed an ex-employee falsified deals worth more than $15 million.
The game attempts to assess whether someone has Alzheimer's by evaluating how well they respond to distractions and interruptions.
In its short history, the New York Genome Center has bulked up quickly to compete with the established genomics powerhouses, advancing from pilot labs at The Rockefeller University to its own 16,000-square-meter site. Now, it is tapping the University of Buffalo for the computing might needed to handle Big Data storage and complex analytics.
The IPO could raise up to $100 million as TPG Capital Funds and other investors look to cash in on the business they took private in 2010 in a $5.2 billion deal.
The new year began with Sanofi and PhRMA trumpeting their commitment to sharing clinical trial data, but the self-congratulation was followed swiftly by fresh criticism of industry practices.
The FDA has made an uneasy transition to the digital era. Congress' watchdog has cataloged its failings, taking potshots at incomplete databases, slow-moving modernization efforts and the lack of a clear IT strategy in recent years. Now, the FDA has moved to clarify its thinking by publishing a 5-year IT investment plan.
President Obama's BRAIN Initiative has begun to take shape over the past 6 months as vague goals have been developed into definite priorities. The process continued recently when the National Institutes of Health (NIH) revealed the 6 projects on which it will invest its first $40 million of BRAIN Initiative funding.
The venture capital wing of Google has once again backed DNAnexus, joining with other existing investors and newcomer Claremont Creek Ventures to commit $15 million.
Open-source companies have had a big impact on parts of IT. The model is being used by Rackspace in cloud computing, Acquia in content management and Red Hat in operating systems. Now a startup out of Harvard Medical School is applying the model to bio Big Data and has raised $1.5 million to advance its ambitions.
Philip Bourne joins NIH from UC San Diego where he uses data mining in pharmacology. He is known to support the free exchange of scientific data.
When struggling Complete Genomics went up for sale last year, it sparked a fight between rival sequencing superpowers BGI and Illumina that touched on national security and a host of other big issues. BGI ultimately won and has now begun to outline its plans for its $119 million acquisition.